Samsung BioLogics entered the biopharmaceutical industry during a time of significant changes. The global availability and capacity for biologics manufacturing are decreasing, and new innovative types of medicines are being developed to help millions suffering from devastating diseases.
Our vision is to become the most competitive CDMO and offer a significant increase in available capacity, quality, and innovation. This will allow our client partners to provide valuable biological medicines to their patients both cost-effectively and on time. To realize this vision, we have built a unique continual processing platform for the manufacturing of biopharmaceutical products with quality and executional excellence in compliance with global regulatory bodies including the FDA, EMA, PMDA, and MFDS.
We pride ourselves in delivering superior customer satisfaction through better quality, superior service, and compliance. Based on Samsung’s principles of Quality First and a track record for excellence in plant design, construction, operations, and execution, our competitiveness surpasses that of our rivals without sacrificing quality, regulatory compliance, or our business ethics. While continuing to implement current industry best practices, we strive together with our clients to set higher standards for biopharmaceutical manufacturing.
Our operations are designed to fully comply with international regulatory and cGMP requirements and are
overseen by our Quality Division. Our advanced facilities are able to manufacture biological products from
early development through commercial supply stages. Furthermore, our experienced people provide
expertise in cell line development, culture, purification, analytical testing, aseptic filling, and packaging.
Our diverse capabilities, manufacturing scale, and flexibility represent a truly integrated
one-stop service that meets all our clients’ needs.
We will continue expanding our facilities and capabilities to meet growing market demand. As a global company, we pledge to continue Samsung’s legacy of excellence by combining our business, manufacturing, and engineering expertise, to bring innovation and progress to today’s biopharmaceutical industry.
Dr. Kyusung Lee is Executive Vice President in charge of Contract Manufacturing Operation 1 of Samsung BioLogics.detail open
Prior to joining Samsung in 2010, Dr. Lee held various leadership positions in biopharmaceutical companies in the U.S.
Dr. Lee began his career with Miller Brewing Company in 1991 as a biochemical engineer. He led the production team for Amoco BioProducts Corporation from 1992 to 1995 and was responsible for the technology transfer of a full scale biotechnology process, after which Dr. Lee moved to Merck & Co. During his tenure at Merck from 1995 to 2005, Dr. Lee participated in the design, construction, start-up, technology transfer, and commercial operation of biologics and pharmaceutical manufacturing facilities.
From 2005 to 2010, Dr. Lee assumed responsibilities for technology transfer activities for Bristol-Myers Squibb Co.'s CMO programs.
Dr. Lee holds a doctoral degree in chemical engineering from Purdue University.
John Rim is Executive Vice President in charge of Contract Manufacturing Operations 2 comprising the newest plant within Samsung BioLogics.detail open
Prior to joining Samsung BioLogics in 2018, Mr. Rim worked for Genentech/Roche in a variety of senior global leadership roles in Technical Operations, Product Development, and Research and Development in the US and Europe.
Mr. Rim has also held senior leadership roles with Astellas Pharmaceuticals in General Management, Sales & Marketing, Technical Operations, Customer Service, Business Development, and Strategic Planning.
Mr. Rim has over 30 years’ experience in the biopharmaceutical industry and began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the US and Europe.
Mr. Rim holds a bachelor’s degree from Columbia University, a master’s degree from Stanford University, and an MBA from the Kellogg School of Management at Northwestern University.
Dongjoong Kim is Senior Vice President and Managing Director in charge of the Business Resources Innovation Center which includes the Finance Team, Business Innovation Team, Corporate Information Technology Team, and Global Employee Satisfaction Team.detail open
Prior to joining Samsung BioLogics in 2014, Mr. Kim held various corporate planning and managerial leadership positions for Samsung Electronics.
Mr. Kim began his career with Samsung in 1988. Mr. Kim led the Corporate Management and Administration of Samsung Electronics from 2002 to 2014.
James Park is Senior Vice President and Managing Director of the Global Business Development Center responsible for BD Operations Team, BD Innovation Team and Integration & Marketing Part of Samsung BioLogics.detail open
Prior to joining Samsung BioLogics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S.
Mr. Park began his career in 1989 with ALZA Corporation, a subsidiary of J & J, as a chemical engineer where he participated and led process and product development, technology transfer, validation and commercialization of several OROS products. He then worked in Technical & Alliance Management at Watson Pharmaceuticals. Transitioning to Merck as a Change Agent/Six Sigma Project Manager, Mr. Park then managed the Operational Excellence projects related to process improvements, cost savings and quality initiatives.
From 2004 to 2015, Mr. Park participated in and directed 100+ CMC due diligences on assets ranging from pre-clinical to commercial products, and managed Global Manufacturing & Supply BD activities including Licensing, Outsourcing and M&A at Bristol-Myers Squibb.
Mr. Park has over 25 years of experience in the biopharmaceutical and pharmaceutical industries.
James Yoon is Vice President and the Managing Director of the CC&C Center responsible for Contract, Legal & Compliance, Communication(PR), Procurement and Contract Development Services of Samsung BioLogics.detail open
Prior to joining Samsung BioLogics in 2011, Mr. Yoon held various corporate planning and managerial leadership positions for Samsung Total Petrochemicals, a Joint Venture Company between Total of France and Samsung.
Mr. Yoon began his career with Samsung in 1986. Mr. Yoon led the business development and financial restructuring of Samsung General Chemicals from 1997 to 2003. Mr. Yoon managed administration for the Joint Venture, including the negotiation of major license agreement for petrochemicals production plants.
Hisung Lee is Vice President and the Team Leader of the SHE Team in EPCV&IGO responsible for the Safety, Health and Environment.detail open
Prior to joining Samsung BioLogics in 2013, technical and managerial leadership positions for Samsung Total Petrochemicals, a Joint Venture Company between Total of France and Samsung.
Mr. Lee began his career with Samsung in 1989. Mr. Lee led the Facility Maintenance and Plant Construction Projects of Samsung Total Petrochemicals from 1993 to 2013.
James Choi is Vice President and Chief Information Officer of the Corporate Information Technology Team responsible for Integration, Validation, Operations, Quality Assurance and Innovation of Samsung BioLogics' IT systems.detail open
Prior to joining Samsung BioLogics in 2014, Mr. Choi held various technology and operations leadership positions at major global healthcare and informatics corporations.
Mr. Choi began his career with Philips Healthcare in 1989 as Site Planning Manager and advanced through leadership positions in Customer Service eBusiness and Technology, Operations, and Information Systems for North America.
Mr. Choi then transitioned to the Informatics and Security industry and was CIO for a major background investigations, insurance intelligence, and commercial pre-employment screening company. Mr. Choi most recently served as CIO for Beckman Coulter’s Clinical Diagnostics and Life Sciences companies.
Mr. Choi has over 25 years of organizational and technology leadership experience in the healthcare and informatics industries.
Andy Yongsin Kim is Vice President and Team Leader responsible for the Global Employee Satisfaction Team and is in charge of overall HR duties at Samsung BioLogics.detail open
Prior to joining Samsung BioLogics in 2010, Mr. Kim was at Samsung Electronics, where he began his career in 1987, as the Director of Human Resources for Visual Display Division.
Most notably, he carried out his duties from 2003 to 2009 by establishing Samsung’s new brand presence in Hungary, managing sales, and overseeing all HR affairs.
Wangoo Hwang is Vice President in charge of Samsung BioLogics’ Plant3 QC.detail open
Prior to joining Samsung BioLogics in 2017, Dr. Hwang was at Samsung Electronics as the Team Leader of Memory Diffusion and Implantation Technology Team.
Chungwoo Lee is Vice President and the Team Leader of the Facility Technology Team in EPCV&IGO responsible for the Facility Maintenance and Utility Operation.detail open
Prior to joining Samsung BioLogics in 2011, Mr. Lee had experienced basic and detail engineering, procurement, construction and validation in petrochemical and biopharmaceutical industries.
Mr. Lee began his career with Samsung Engineering in 1995.
After joining Samsung BioLogics, he led the Plant 1 and Plant 2 Engineering, Procurement, Construction & Validation of Samsung BioLogics from 2011 to 2015.
Byunghwa Shim is Vice President and the Team Leader responsible for the Business Innovation Team of Samsung BioLogics.detail open
Mr. Shim began his career with Samsung in 1991.
Prior to joining Samsung BioLogics in 2011, Mr. Shim was at Samsung C&T leading overall finance.
Samsung BioLogics (hereinafter, the “Company”) values users’ personal information, complies with statutory obligation s on protection of personal information such as the Act on Promotion of Information and Communication Network Utilization and Information Protection, etc. and the Act on Protection of Personal Information, and has created a Policy to Handle (Process) Personal Information to protect the users’ right and interest to the maximum extent possible.
Through the Policy to Handle (Process) Personal Information, the Company publicizes its operations on personal information treatment (processing) with particulars such as the types of personal information collected from the users and the purpose of processing such information, the time limit for processing and holding in possession, users’ method to exercise their rights, measures to procure the security, and so on.
Whenever there is a change in the Policy to Handle (Process) Personal Information, including updating, deleting, or adding its contents, whether resulting from any amendment to the relevant statutory sources or the administrative policy or change in the Company’s internal policy, we will post the change on our website at www.samsungbiologics. com so as to keep the users updated.
The Company’s Policy to Handle (Proce ss) Personal Information contains the following:
The Company collects personal information for the following purposes. The pfi will not be used for any other purpose and whenever it is necessary to change the purpose, we will comply with the statutory requirements such as obtaining users’ consents in advance.
Review and reply to the inquiries from users
Check employment history, give notices for future recruitment opportunities.
|Required||Name, Email Address, Company, Occupation, Country, Areas of Interest|
|Optional||Job Title, Phone Number|
The following information may be generated and collected in the course of using the service.
Access long, cookie
Collection through Contact Us, Talent Pool within the Website
Collection through generated information collection tool (for access long, cookie, etc.)
Personal information that needs to be collected and utilized inevitably as specifically required by law or regulations, or in order to comply with statutory requirements : As long as it is necessary to keep such information in possession under relevant statute.
Personal information that needs to be collected and utilized inevitably in order to execute and perform various contracts: Until the purpose of collection/utilization is accomplished.
Personal information collected and used with the consent of individual user: For the time period consented to.
If the user has given his/her consent in advance.
If it is specifically required by laws or regulations or inevitable in order to comply with statutory requirements, or if it is deemed necessary for the sake of life, body or property of the information owner or a third party when the information owner or his/her legal representative is under a state incapable of communication or unable to give consent due to unknown domiciles or otherwise (only to the extent the purpose of collecting personal information is served).
User’s personal information
History of the users personal information being utilized or provided to a third party
History of consents given to collection, utilization and provision of personal information
If it is specifically required by laws or regulations or inevitable in order to comply with statutory requirements.
If it is likely to jeopardize a person’s life or body or unjustly infringe a person’s property or other interests.
The Company is operating cookies that regularly stores and locates users’ information.
How to install cookies (if using Internet explorer 8.0) Select “Internet Option” in the “Tool”. Click “Privacy” tab. Using “Setting”, users may set the level of allowing cookies as suitable for their own needs.
How to view the cookie received (if using Internet explorer 8.0)
Select “Internet Option” in the “Tool”. Click “General” tab and select “Setting” of the Browsing History to check the files in “View Files”.
How to disallow cookie installation (if using Internet explorer 8.0) Select “Internet Option” in the “Tool”. Click “Privacy” tab. Using “Setting”, set it to the higher level, that is, “Block All Cookies”
in handling users’personal information, the Company endeavors to keep the personal information from being lost, stolen, revealed, tampered or damaged. To this end, the following technical and managerial actions are taken.
The Company implements its own internal management plan to secure safety in processing the personal information.
The Company is operating an internal organization dedicated to personal information protection to monitor the status of compliance with the personal information protective requirements and the responsible staff’s duty performance and takes corrective measures when any irregularity is found.
Installation and operation of access restriction device Using the intrusion blocking system, the Company controls any unauthorized access from outside and endeavors to procure all the technological system to the maximum extent feasible in order to secure systematic security.
Minimized designation of personal information processors and education The Company minimizes designation of personal information processors and implements internal and/or outsourced education on a regular basis. Personal information processors’ duty handover is conducted with the security fully maintained and their responsibilities for any personal information accident are clearly defined even after they have left the Company.
Restrictions on access to personal information The Company places restrictions on access to personal information through granting, changing or revoking the right to access to database system that processes personal information. We also record the history of granting, changing or revoking the right, which are retained for our records for at least three years.
The personal information of users is protected by the password and the file and transmission data are encrypted or stored by using file lock function. More important data are protected through certain separate security measures.
The Company has adopted security devices that enable safe transmission of personal information on the network using encryption algorithm.
To safeguard personal information from leak or loss by hackers or computer viruses, the Company has installed a security program and conducts periodic updating and reviewing.
For unmistakable security operation, every server is installed with intrusion blocking system as a means to block outsider intrusion by hacking as well as a system to analyze vulnerability.
To protect users’personal information and handle personal information-related customer complaint, the Company has appointed a personal information manager and processor. Any inquiry related to personal information protection and management should be directed to the personal information processor for instant and adequate reply.
Division: General Affairs Security Part, Personnel Management Team
Any user seeking to relief from personal information infringement may apply for resolution or consultation to Personal Information Dispute Mediation Committee, Korea Internet and Security Agency (Personal Information Grievance Center). In addition, users may contact the following institutions to be consulted on personal information infringement cases.
Personal Information Dispute Mediation Committee (118)
Korea Internet and Security Agency (Personal Information Grievance Center)(www.kopico.or.kr/1336)
Information Protection Mark Verification Committee (http://eprivacy.or.kr/02-580-0533~4)
Internet Crime Investigation Center of the Supreme Prosecutors’ Office
Cyber Police Agency (www.police.go.kr/1566-0112)
Personal information Protection Committee (http://privacy.kisa.or.kr/kor/main.jsp)/02-2180-3000)
When this ‘Policy to Handle (Process) Personal Information’ needs to be changed to reflect the change in statutory sources or government policies, we will put such change in public notice through an advisory statement and a separate window on the website.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.